Black Diamond Therapeutics Long Term Debt

Black Diamond Therapeutics (BDTX) currently reports a long-term debt of $14M as of March 2026. That compares with $18M in the prior-year period — down 21.2% year over year. Use the charts on this page to explore Black Diamond Therapeutics's long-term debt history and peer comparisons.

Black Diamond Therapeutics's long-term debt decreased from $18M to $14M — a 21.2% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Black Diamond Therapeutics reported $14M in long-term debt as of March 2026. That compares with $18M in the prior-year period — down 21.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $14M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Black Diamond Therapeutics, and consider following BDTX for alerts when major investors trade the stock.

Black Diamond Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $14M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BDTX with unrelated industries.